HSBC/CALL/ABBOTT LABORATORIES/120/0.1/15.01.25 Stock

Warrant

DE000HG80CY5

Market Closed - Bid/Ask 02:21:03 2024-06-05 am EDT Pre-market 02:23:35 am
0.174 EUR 0.00% Intraday chart for HSBC/CALL/ABBOTT LABORATORIES/120/0.1/15.01.25 0.187 +7.47%
Current month+19.18%
1 month-43.87%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-05 0.174 0.00%
24-06-04 0.174 -0.57%
24-06-03 0.175 +19.86%
24-05-31 0.146 -7.59%
24-05-30 0.158 +17.04%

Real-time Boerse Frankfurt Warrants

Last update June 05, 2024 at 02:21 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ABBOTT LABORATORIES
Issuer HSBC
WKN HG80CY
ISINDE000HG80CY5
Date issued 2023-02-02
Strike 120 $
Maturity 2025-01-15 (225 Days)
Parity 10 : 1
Emission price 1.24
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.38
Lowest since issue 0.119
Spread 0.029
Spread %14.50%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
103.4 USD
Average target price
125.4 USD
Spread / Average Target
+21.22%
Consensus